Study of RAPA-201 cell therapy for advanced melanoma
Part of Cancer, Skin clinical trials.
This trial tests an experimental cell therapy made from your own immune cells to fight advanced melanoma that hasn't responded to standard immunotherapy. The goal is to see if this treatment can help people whose melanoma has stopped responding to current drugs.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- You have advanced melanoma (stage IIIc or IV) that can't be removed with surgery or has spread.
- You've already tried an immunotherapy drug (like pembrolizumab, nivolumab, or atezolizumab) and it stopped working.
- If you have a BRAF gene mutation, you've also been treated with targeted therapy (BRAF or MEK inhibitors).
- You must be well enough to have your own white blood cells collected to make the study treatment.
- You need to have normal blood counts and organ function, and be free of serious heart or bleeding issues.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1/2 trial tests RAPA-201, a personalized immune cell treatment made from your own T cells, for advanced solid tumors. It may help people whose cancer has come back after standard treatment and after an anti–PD-1/PD-L1 antibody.
This trial tests a new type of cell therapy using your own immune cells (NK cells) modified to target a protein called PRAME found on melanoma cells. It is for people whose melanoma has not responded to or has returned after standard immunotherapies.
This trial tests a new drug that helps your immune system find and attack cancer cells that have a specific marker (MAGE-A1). It's for people with advanced solid tumors who have run out of standard options.
This trial tests a new drug called RPTR-1-201 for people with advanced solid tumors that have not responded to standard treatments. It aims to see if the drug is safe and effective.
This trial tests an experimental drug called RP-001 in people with advanced or metastatic cancer that has not improved with standard treatment. It aims to see if the drug is safe and how well it works.
This trial tests a new drug called PRJ1-3024 for people with advanced melanoma that has not responded to standard treatment. The goal is to see if the drug can shrink tumors or slow the cancer's growth.
Hear when a new Malignant Melanoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.